The AAPS Journal

, 22:2 | Cite as

Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms

  • Connie LangerEmail author
  • Dorys Argelia Diaz
  • Leslie Van Alstine
  • Nagesh Bandi
  • Sarah Fitzgerald
  • Stephen Colgan
Research Article


This manuscript discusses global regulatory divergence of dissolution requirements for modified release solid oral dosage forms and the obstacles that must be addressed to be compliant with evolving guidance and legislation. The proliferation of local guidance documents, changing regulatory expectations, and increased legal enforcement has resulted in mismatched country-specific dissolution testing requirements and similarity criteria, and heightens industry’s challenges with registration of modified release solid oral dosage forms. The lack of global harmonization and the complexity added by minor regional adaptations contributes to inefficiencies and hinders industry’s goal of developing and delivering medicines. Awareness of country-specific similarity requirements and alignment between industry leaders and regulators is needed to facilitate global harmonization which will enable delivering new and improved medicines. The purpose of this manuscript is to compare and contrast in vitro conditions stated in local regulatory guidelines, raise awareness of the need to work toward harmonization of global requirements, and propose an initial study design toward that aspiration.


dissolution harmonization modified release 



The authors would like to thank Roger Nosal, Michael Likar, John Groskoph, Beth Kendsersky, Loren Wrisley, Ron Ogilvie, Michael Cohen, Megan McMahon, Ling Zhang, and Gregg Kelly for reviewing and providing helpful comments on this paper.


  1. 1.
    Department of Health, Therapeutic Goods Administration, Australia. Guidance 15: biopharmaceutic studies, no. Version 1.1, April 2015.Google Scholar
  2. 2.
    National Health Surveillance Agency, Brazil. About the studies of pharmaceutical equivalence and comparative dissolution profile. Collegiate Directory, Vols Resolution-RDC No 31, August 2010.Google Scholar
  3. 3.
    Health Canada. Drugs and Health Products.Post-notice of compliance (NOC) changes: quality document. Vols. File Number 13–107786-650, 2013.Google Scholar
  4. 4.
    China FDA. Center for Drug Evaluation. Technical guidelines for supplementary application of chemical drugs (the second draft). 2015.Google Scholar
  5. 5.
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on quality of oral modified release products, vol. EMA/CHMP/QWP/428693/2013, 2014.Google Scholar
  6. 6.
    Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, Government of India. Guideline for bioavailability and bioequivalence studies. 2005.Google Scholar
  7. 7.
    Pharmaceutical and Food Safety Bureau, Japan. Guideline for bioequivalence studies of oral solid preparations with different strengths, Vols. PMSB/ELD Notification Number 64, revised November 24, 2006, February 2001.Google Scholar
  8. 8.
    Pharmaceutical Food and Safety Bureau, Japan. Guideline for bioequivalence studies of oral solid formulations with formulation changes, Vols. PMSB/ELD Notification Number 67, Revised November 2006, February 2000.Google Scholar
  9. 9.
    Pharmaceutical and Food Safety Bureau, Japan. The guideline for bioequivalence studies for supplemental formulations with different dosage forms, vol. PMSB/ELD Notification Number 783, May 2001.Google Scholar
  10. 10.
    Pharmaceutical and Food Safety Bureau, Japan. Q&A on: guideline for bioequivalence test on oral solid preparation with different drug contents, Guideline for bioequivalence test on Oral solid preparation which the formulation has been changed, " Vols. PFSB/ELD Notice, Revised November 2001, May 2001.Google Scholar
  11. 11.
    L. a. W. (. Ministry of Health, "Supplement II to the Japanese pharmacopoeia," Promulgated by Ministerial Notification, no. No.65, March 24, 2011.Google Scholar
  12. 12.
    Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). Official Mexican Standard NOM-177-SSA1–2013. Official Gazette; 2013.Google Scholar
  13. 13.
    Federal Service on Surveillance in Healthcare and Social Development. Methodological recommendations for drug manufacturers on in vitro equivalence test for generic drug products according to biowaiver procedure. 2012.Google Scholar
  14. 14.
    Drug Control Division, Thailand. Guidelines for the Conduct of bioavailability and bioequivalence studies adopted from “ASEAN Guidelines for the Conduct of Bioavailability and Bioequivalence Studies, 2009.Google Scholar
  15. 15.
    ASEAN Guideline for the conduct of bioequivalence studies. (8th PPWG meeting, Bangkok); 2004.Google Scholar
  16. 16.
    Ministry of Health, Republic of Turkey. Pharmaceuticals and pharmacy general directorate number B.10.0.IEG. vol. On Bioequivalence Files 24305.Google Scholar
  17. 17.
    Medicines Control Council, Department of Health, Republic of South Africa. Registration of Medicines: dissolution, vol. Version 2. 2007.Google Scholar
  18. 18.
    Korea Ministry of Food and Drug Safety. KFDA guidelines for Comparative Dissolution Test. Vols. KFDA Notification No. 2010–44. 2010.Google Scholar
  19. 19.
    Korean Pharmacopoeia. Ministry of Food and Drug Safety Notification No. 2018–16. Vols. 03. 08, Amended, 2018.Google Scholar
  20. 20.
    FDA Guidance For Industry. SUPAC-MR: modifed release solid oral dosage forms. 1997.Google Scholar
  21. 21.
    FDA Guidance for Industry. Extended release oral dosage forms:development, evaluation, and application of in vitro/in vivo correlations. vol. BP2, September 1997.Google Scholar
  22. 22.
    FDA Guidance For Industry. Bioavailability and bioequivalence studies for orally administered drug products, general considerations. 2003.Google Scholar
  23. 23.
    Pharmaceuticals and Medical Devices Agency, Japan. Guideline for Bioequivalence studies for formulation changes of oral solid dosage forms. English translation of Attachment 3 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safet Bureau. 2012.Google Scholar
  24. 24.
    United States Pharmacopeia, "<711> DISSOLUTION," 2011.Google Scholar
  25. 25.
    Shargel L, Yu A, Wu-Pong S. Applied biopharmaceutics and pharmacokinetics. 6th ed. New York: McGraw Hill Medical; 2012.Google Scholar
  26. 26.
    Diaz DA, Colgan ST, Langer CS, Likar M, Van Alstine L, Bandi N. Dissolution similarity requirements: how similar or dissimilar are the global regulatory expectations? AAPS J. 2016;18(1):15–22.CrossRefGoogle Scholar
  27. 27.
    European Medicines Agency. Question and answer on the adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles. EMA/810713/2017 Human Medicines Research and Development Support, 26 July 2018.Google Scholar
  28. 28.
    Hirschler B. Ex-FDA head and Sanofi call for harmonized drug regulation. Reuters, May 2016.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Connie Langer
    • 1
    Email author
  • Dorys Argelia Diaz
    • 1
  • Leslie Van Alstine
    • 2
  • Nagesh Bandi
    • 3
  • Sarah Fitzgerald
    • 4
  • Stephen Colgan
    • 1
  1. 1.Global Product Development, Global Chemistry, Manufacturing & ControlsPfizer Inc.GrotonUSA
  2. 2.Global Product Development, Analytical Research & DevelopmentPfizer Inc.GrotonUSA
  3. 3.GRACS - CMC; Pre-approval Pharm & New ProductsMerck & Co. Inc.RahwayUSA
  4. 4.Chemistry, Manufacturing & ControlsAlexion Pharmaceuticals Inc.BostonUSA

Personalised recommendations